<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tinea versicolor (pityriasis versicolor)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tinea versicolor (pityriasis versicolor)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tinea versicolor (pityriasis versicolor)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth G Goldstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam O Goldstein, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tinea versicolor (ie, pityriasis versicolor) is a common superficial fungal infection that typically presents with hypopigmented, hyperpigmented, or erythematous macules on the trunk and proximal upper extremities  (<a class="graphic graphic_picture graphicRef100026 graphicRef100022 graphicRef100020 graphicRef100019 graphicRef100021" href="/d/graphic/100026.html" rel="external">picture 1A-E</a>). Unlike many other disorders utilizing the term "tinea" (eg, tinea pedis, tinea capitis), tinea versicolor is not a dermatophyte infection. The causative organisms are in the genus <em>Malassezia</em> (formerly known as <em>Pityrosporum</em>).</p><p>Tinea versicolor typically responds well to therapy  (<a class="graphic graphic_algorithm graphicRef142461" href="/d/graphic/142461.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef100541" href="/d/graphic/100541.html" rel="external">table 1A</a>), but recurrence is common and long-term prophylactic therapy may be necessary. The clinical features, diagnosis, and management of tinea versicolor will be reviewed here. Other cutaneous superficial fungal infections are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99983.html" rel="external">"Tinea capitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/110106.html" rel="external">"Tinea nigra"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/115366.html" rel="external">"Intertrigo", section on 'Pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Tinea versicolor occurs worldwide.</p><p>Tinea versicolor most commonly affects adolescents and young adults but can also occur in children and infants [<a href="#rid1">1-4</a>]. The disorder is not considered contagious, although successful inoculation has occurred under experimental conditions utilizing topical oils and occlusion [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H1092812488"><span class="h1">PATHOGENESIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causative organisms</strong> – The causative organisms are saprophytic yeasts in the genus <em>Malassezia</em> (formerly known as <em>Pityrosporum</em>) [<a href="#rid7">7</a>]<em>. Malassezia</em> is a lipid-dependent, dimorphic fungus that is a component of normal skin flora. Transformation of<em> Malassezia</em> from yeast cells to a pathogenic, mycelial form is associated with the development of clinical disease.</p><p></p><p class="bulletIndent1"><em>Malassezia globosa</em> appears to be the predominant causal species [<a href="#rid8">8-10</a>]. <em>Malassezia sympodialis</em>, <em>Malassezia furfur</em>, and other <em>Malassezia</em> species have also been implicated [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/2428.html" rel="external">"Invasive Malassezia infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sites of predilection</strong> – The distribution of tinea versicolor on the body may reflect the nutritional requirements of the yeast. <em>Malassezia</em> is lipid dependent, and the greater sebum production by cutaneous sebaceous glands on the upper body may contribute to the predominance of tinea versicolor in this location. This theory may also account for the less frequent occurrence of this disorder in children and older adults, in whom sebum production is lower [<a href="#rid7">7,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pigmentary change</strong> – Although the reasons for pigmentary variation in tinea versicolor are unconfirmed, theories have been proposed. Patients with hypopigmented tinea versicolor often notice that the disorder is most prominent during the summer, when the affected areas fail to tan after sun exposure. Inhibitory or damaging effects on melanocytes by <a class="drug drug_general" data-topicid="9038" href="/d/drug information/9038.html" rel="external">azelaic acid</a> (a dicarboxylic acid produced by <em>Malassezia</em>) may play a role in the development of hypopigmentation [<a href="#rid13">13,14</a>]. Hyperpigmented and erythematous lesions may be a consequence of an inflammatory reaction to the yeast [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H1802415541"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>External factors suspected of contributing to the transformation of <em>Malassezia</em> from yeast cells to a pathogenic, mycelial form include exposure to hot and humid weather, hyperhidrosis, and the use of topical skin oils [<a href="#rid15">15</a>]. Tinea versicolor is not related to poor hygiene.</p><p>Host characteristics that contribute to the development of tinea versicolor are poorly understood. A genetic predisposition may be involved [<a href="#rid16">16</a>]. In a questionnaire-based study, 21 percent of patients reported a positive family history of the disease [<a href="#rid17">17</a>]. Tinea versicolor also occurs more commonly in patients who are immunosuppressed, suggesting that an altered host immune response may play a role in the pathogenesis [<a href="#rid18">18</a>]. One case report describes extensive tinea versicolor after the initiation of the biologic interleukin (IL) 17 inhibitor <a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">ixekizumab</a> [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphology</strong> – The multiple macules, patches, and thin plaques of tinea versicolor can be hypopigmented, hyperpigmented, or mildly erythematous  (<a class="graphic graphic_picture graphicRef100026 graphicRef100022 graphicRef100020 graphicRef100019 graphicRef100021" href="/d/graphic/100026.html" rel="external">picture 1A-E</a>). The term "versicolor" refers to the variable changes in cutaneous pigmentation that occur.</p><p></p><p class="bulletIndent1">The color of hyperpigmented tinea versicolor ranges from light brown to gray-black. In individuals with moderately to highly pigmented skin, hyperpigmented tinea versicolor often presents as dark brown to gray-black lesions  (<a class="graphic graphic_picture graphicRef52438" href="/d/graphic/52438.html" rel="external">picture 2</a>), and in individuals with lightly to moderately pigmented skin, hyperpigmented tinea versicolor is often light brown to medium brown  (<a class="graphic graphic_picture graphicRef100019" href="/d/graphic/100019.html" rel="external">picture 1D</a>).</p><p></p><p class="bulletIndent1">Individual lesions are typically small (eg, &lt;15 mm) and oval or round but frequently coalesce into larger patches or thin plaques. A fine scale is often present, which becomes more apparent when the lesion is scraped for microscopy. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – In adolescents and adults, tinea versicolor is most commonly found on the upper trunk and proximal upper extremities and less often on the face and intertriginous areas. In contrast, when tinea versicolor occurs in children, facial involvement is common  (<a class="graphic graphic_picture graphicRef100025 graphicRef100024" href="/d/graphic/100025.html" rel="external">picture 3A-B</a>) [<a href="#rid1">1,7</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Most patients are asymptomatic; occasional patients report mild pruritus. In our experience, the appearance of skin lesions is often the primary concern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Course</strong> – Tinea versicolor may persist for years without treatment [<a href="#rid20">20</a>]. Recurrence is common after successful treatment [<a href="#rid20">20</a>]. In temperate climates, tinea versicolor often recurs during the warmer months of the year.</p><p></p><p class="bulletIndent1">Spontaneous resolution is possible; low rates of resolution have been documented in placebo groups in randomized trials [<a href="#rid21">21</a>]. (See <a class="local">'Management'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Tinea versicolor should be considered when a patient presents with multiple coalescing, hypopigmented or hyperpigmented macules, patches, or thin plaques on the upper trunk, proximal extremities, neck, or face. Although the diagnosis may be strongly suspected based upon the physical examination, confirmation of the diagnosis with a potassium hydroxide (KOH) preparation should be performed when the diagnosis is uncertain. The variable clinical features of tinea versicolor overlap with the clinical features of other skin diseases. (See <a class="local">'Clinical features'</a> above and <a class="local">'Differential diagnosis'</a> below.)</p><p><em>Malassezia</em> species are normal components of skin flora, and detection of <em>Malassezia</em> species through culture or molecular methods is not considered diagnostic [<a href="#rid22">22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – A full skin examination should be performed. Performance of a full skin examination allows for the recognition of the degree of skin involvement as well as clinical findings that are inconsistent with tinea versicolor. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Dermoscopy and Wood's lamp examination may exhibit features suggestive of tinea versicolor but do not confirm the diagnosis. Frequent dermoscopic findings appear to be nonuniform pigmentation within lesions, fine scale, and perilesional hyperpigmentation or hypopigmentation [<a href="#rid23">23-25</a>]. Other features have also been reported [<a href="#rid23">23-25</a>]. Examination with a Wood's lamp reveals yellow to yellow-green fluorescence in some patients. It is estimated that fluorescence is present in less than 50 percent of patients [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Wood's lamp examination (black light)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potassium hydroxide preparation</strong> – The KOH preparation findings in tinea versicolor are considered diagnostic. The preparation demonstrates both short hyphae and yeast cells in a pattern that is often described as "spaghetti and meatballs"  (<a class="graphic graphic_picture graphicRef58965" href="/d/graphic/58965.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of tinea versicolor consists of common and uncommon skin disorders. The potassium hydroxide (KOH) preparation is a simple and reliable way to distinguish tinea versicolor from other conditions. (See <a class="local">'Diagnosis'</a> above.)</p><p>Examples of skin disorders that may resemble tinea versicolor include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common inflammatory disorders</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seborrheic dermatitis</strong> – Seborrheic dermatitis on the trunk may present as erythematous, hypopigmented, or hyperpigmented patches or thin patches. In contrast to tinea versicolor, seborrheic dermatitis typically has thicker scale. Patients often exhibit other areas of involvement, such as the scalp, eyebrows, and nasolabial folds  (<a class="graphic graphic_picture graphicRef114660 graphicRef126095" href="/d/graphic/114660.html" rel="external">picture 5A-B</a>). (See  <a class="medical medical_review" href="/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pityriasis rosea</strong> – Patients with classic pityriasis rosea present with inflammatory macules and small patches in a "Christmas tree-like" distribution on the trunk. A larger herald patch that precedes the widespread eruption is often noted. Lesions may exhibit erythema and a collarette of scale  (<a class="graphic graphic_picture graphicRef98333 graphicRef87126" href="/d/graphic/98333.html" rel="external">picture 6A-B</a>). In individuals with highly pigmented skin, hyperpigmentation is sometimes prominent  (<a class="graphic graphic_picture graphicRef98334" href="/d/graphic/98334.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/d/html/5665.html" rel="external">"Pityriasis rosea"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pityriasis alba</strong> – Pityriasis alba is a mild form of eczematous dermatitis that presents with hypopigmented macules and small patches on the face and, less frequently, on the upper extremities  (<a class="graphic graphic_picture graphicRef60866 graphicRef73576" href="/d/graphic/60866.html" rel="external">picture 8A-B</a>). Fine scale may be visible. The disorder is most common in children with an atopic history. (See  <a class="medical medical_review" href="/d/html/103736.html" rel="external">"Acquired hypopigmentation disorders other than vitiligo", section on 'Pityriasis alba'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious disorders</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythrasma </strong>– Erythrasma may present with erythematous or hyperpigmented patches in the axillae or groin and is included in the differential diagnosis of intertriginous tinea versicolor  (<a class="graphic graphic_picture graphicRef59529 graphicRef51713" href="/d/graphic/59529.html" rel="external">picture 9A-B</a>). Sites of erythrasma exhibit coral-red fluorescence upon illumination with a Wood's lamp  (<a class="graphic graphic_picture graphicRef62143" href="/d/graphic/62143.html" rel="external">picture 10</a>). (See  <a class="medical medical_review" href="/d/html/4031.html" rel="external">"Erythrasma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary syphilis </strong>– Patients with secondary syphilis may present with erythematous to brown macules, papules, or small plaques in a generalized distribution  (<a class="graphic graphic_picture graphicRef60313" href="/d/graphic/60313.html" rel="external">picture 11</a>). Skin involvement is often present on the palms and soles  (<a class="graphic graphic_picture graphicRef65500" href="/d/graphic/65500.html" rel="external">picture 12</a>). (See  <a class="medical medical_review" href="/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other disorders</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Terra firma-forme dermatosis</strong> – Terra firma-forme dermatosis is a benign condition in which retention hyperkeratosis leads to the appearance of hyperpigmented papules or plaques that can resemble dirty skin  (<a class="graphic graphic_picture graphicRef94427 graphicRef94203" href="/d/graphic/94427.html" rel="external">picture 13A-B</a>) [<a href="#rid26">26</a>]. Common locations are the neck and ankle. In contrast to tinea versicolor, lesions are easily removed with an alcohol swab. (See  <a class="medical medical_review" href="/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders", section on 'Terra firma-forme dermatosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitiligo </strong>– Vitiligo is an acquired disorder of pigmentation characterized by completely depigmented macules and patches  (<a class="graphic graphic_picture graphicRef79198 graphicRef129928" href="/d/graphic/79198.html" rel="external">picture 14A-B</a>). In contrast, tinea versicolor exhibits hypopigmented skin lesions. (See  <a class="medical medical_review" href="/d/html/105109.html" rel="external">"Vitiligo: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Confluent and reticulated papillomatosis of Gougerot and Carteaud </strong>–<strong> </strong>This uncommon cutaneous disorder usually occurs in young adults. Hyperpigmented, scaly patches with a reticulated appearance are the characteristic findings  (<a class="graphic graphic_picture graphicRef67566 graphicRef76296 graphicRef54172 graphicRef66671" href="/d/graphic/67566.html" rel="external">picture 15A-D</a>). The neck, chest (particularly intermammary area), and upper back may be affected. (See  <a class="medical medical_review" href="/d/html/101429.html" rel="external">"Confluent and reticulated papillomatosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mycosis fungoides </strong>– Mycosis fungoides may present as hypopigmented patches on the skin, with a predilection for the trunk and extremities  (<a class="graphic graphic_picture graphicRef71926" href="/d/graphic/71926.html" rel="external">picture 16</a>). Fine scale, erythema, or infiltrated plaques may also be present. (See  <a class="medical medical_review" href="/d/html/15872.html" rel="external">"Variants of mycosis fungoides", section on 'Hypopigmented mycosis fungoides'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H893936734"><span class="h2">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical therapy is the treatment of choice</strong> [<a href="#rid20">20</a>]. Oral therapy is generally reserved for scenarios in which adequate application of topical therapy is not feasible (eg, extensive disease or limited ability of the patient to administer topical treatment) and for refractory or recurrent disease  (<a class="graphic graphic_algorithm graphicRef142461" href="/d/graphic/142461.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef100541" href="/d/graphic/100541.html" rel="external">table 1A</a>) [<a href="#rid27">27</a>]. (See <a class="local">'Refractory disease or extensive disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperpigmentation and hypopigmentation often persist for weeks to a few months after successful treatment. </strong>Because resolution of skin discoloration is often delayed, an assessment for signs of active infection is indicated prior to assuming treatment failure. (See <a class="local">'Confirming treatment failure'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-quality comparative studies of treatments for tinea versicolor are limited, making the optimal approach to treatment unclear.</strong> A systematic review and meta-analysis of controlled trials found that most trials that compared treatment regimens or therapeutic agents were underpowered to detect meaningful differences [<a href="#rid28">28</a>]. The results suggested that longer courses of treatment, higher concentrations of topical active ingredients, and higher doses of oral antifungals may improve cure rates. However, additional studies are necessary to confirm this conclusion. (See <a class="local">'Initial therapy'</a> below and <a class="local">'Refractory disease or extensive disease'</a> below and <a class="local">'Other therapies'</a> below.)</p><p></p><p class="bulletIndent1">The methods and timing of response assessment vary across studies. The physical examination and/or microscopic assessment is often used to assess treatment outcomes. The term "mycologic cure" usually refers to a negative potassium hydroxide (KOH) preparation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H76227885"><span class="h2">Patient education</span><span class="headingEndMark"> — </span>Important patient education concepts include the cause and expected course of tinea versicolor. We inform patients that tinea versicolor is not due to poor hygiene, that it is not contagious, that it usually responds well to treatment, and that recurrence is common. In addition, because persistent, pigmentary changes can be mistaken for active infection, we inform patients that skin discoloration may take weeks to a few months to resolve. (See <a class="local">'Confirming treatment failure'</a> below and <a class="local">'Information for patients'</a> below.)</p><p class="headingAnchor" id="H76227692"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>Topical azole antifungal drugs, topical <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, and topical <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> are our preferred initial therapies, as these modalities are generally well tolerated and have the most data to support treatment efficacy  (<a class="graphic graphic_algorithm graphicRef142461" href="/d/graphic/142461.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef100541" href="/d/graphic/100541.html" rel="external">table 1A</a>) [<a href="#rid28">28</a>]. Selection of a specific agent is generally based upon treatment availability and patient preference (eg, preference for a specific vehicle [eg, shampoo versus cream], treatment duration, or cost). Topical <a class="drug drug_general" data-topicid="10237" href="/d/drug information/10237.html" rel="external">zinc pyrithione</a> is a reasonable alternative. Other topical interventions may also be effective. (See <a class="local">'Alternative therapy'</a> below and <a class="local">'Other therapies'</a> below.)</p><p class="headingAnchor" id="H3382271823"><span class="h3">Topical azole antifungal drugs</span><span class="headingEndMark"> — </span>Topical azole antifungal drugs have direct antifungal activity and are considered effective for tinea versicolor  (<a class="graphic graphic_table graphicRef100541 graphicRef76148" href="/d/graphic/100541.html" rel="external">table 1A-B</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Topical azole antifungal drugs are available in a variety of formulations, including shampoos, creams, foams, gels, and solutions  (<a class="graphic graphic_table graphicRef76148" href="/d/graphic/76148.html" rel="external">table 1B</a>). <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> 2% shampoo is our preferred formulation because of demonstrated efficacy of a short course of treatment and the relative ease of application of shampoo to large body areas. However, use of other topical azole antifungal drugs is reasonable. Examples of other formulations with evidence of efficacy include <a class="drug drug_general" data-topicid="9287" href="/d/drug information/9287.html" rel="external">clotrimazole</a>, bifonazole, <a class="drug drug_general" data-topicid="16763" href="/d/drug information/16763.html" rel="external">miconazole</a>, and <a class="drug drug_general" data-topicid="9400" href="/d/drug information/9400.html" rel="external">econazole</a> [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> 2% shampoo is applied to affected areas and washed off after five minutes. We typically advise patients to treat for three consecutive days. A typical treatment course for other formulations of ketoconazole (eg, cream, foam) and other topical azole antifungal drugs is daily application for two weeks. However, shorter durations may be sufficient for some treatments [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1">Efficacy of a one-day regimen for <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% shampoo has also been reported [<a href="#rid33">33</a>]. However, given the frequent location of tinea versicolor in body sites that can be challenging to view and reach, the potential for environmental or patient-specific factors to influence the efficacy of treatment, and the minimal risks of treatment, we typically advise patients to treat for three days to increase the likelihood of adequate treatment.</p><p></p><p class="bulletIndent1">Unlike the 2% formulation, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 1% shampoo is available without a prescription in the United States. Although ketoconazole 1% shampoo is sometimes used for tinea versicolor in clinical practice, its efficacy for tinea versicolor has not been evaluated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Multiple small, randomized trials support the efficacy of various topical azole antifungal drugs compared with placebo [<a href="#rid21">21,28</a>]. For example, in one randomized trial (n = 101), <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% cream applied once daily for 11 to 22 days (mean 14 days) was superior to placebo (mycologic cure in 84 versus 22 percent of patients) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Another trial found three-day and one-day regimens for <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% shampoo more effective than placebo and found similar efficacy for the two ketoconazole regimens [<a href="#rid33">33</a>]. In the trial, 322 patients with tinea versicolor were randomly assigned to a five-minute application of ketoconazole 2% shampoo for one day, ketoconazole 2% shampoo for three days, or placebo shampoo for three days. At day 31, rates of mycologic cure (based upon cellophane tape test results for 310 patients) were 78, 84, and 11 percent, respectively.</p><p></p><p class="bulletIndent1">A randomized trial (n = 40) that compared once-daily application of <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% cream for 14 days with once-daily application of <a class="drug drug_general" data-topicid="9287" href="/d/drug information/9287.html" rel="external">clotrimazole</a> 1% cream for 14 days did not find a statistically significant difference in efficacy [<a href="#rid35">35</a>]. Azole antifungal drugs have also been compared with other types of treatments [<a href="#rid21">21</a>]. (See <a class="local">'Topical terbinafine'</a> below and <a class="local">'Selenium sulfide'</a> below.)</p><p></p><p class="headingAnchor" id="H2502688098"><span class="h3">Topical terbinafine</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> is an allylamine antifungal drug.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">Terbinafine</a> is available as a nonprescription 1% cream in the United States as well as in a solution form in some other locations. Various treatment regimens have been utilized, ranging from once- to twice-daily application for one to four weeks [<a href="#rid21">21</a>]. A reasonable regimen is twice-daily application for one week.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Topical <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> 1% solution applied twice daily for one week has been effective in randomized trials [<a href="#rid21">21</a>]. In one of the largest trials (n = 288), twice-daily application of terbinafine 1% solution was superior to placebo [<a href="#rid36">36</a>]. Mycologic cure rates at week 8 were 64 and 33 percent, respectively.</p><p></p><p class="bulletIndent1">Smaller, randomized trials comparing <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a> 1% cream with similar application regimens of <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% cream (once- or twice-daily application for 14 days), bifonazole cream (twice-daily application for up to four weeks), or eberconazole 1% cream (once daily for two weeks) have not found statistically significant differences in efficacy among the treatments [<a href="#rid37">37-40</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Selenium sulfide</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> exerts antifungal activity primarily through the promotion of shedding of the infected stratum corneum.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">Selenium sulfide</a> is available as a 2.25% or 2.5% shampoo and a 2.5% lotion (depending on location). A reasonable regimen for these formulations is application to the affected area once daily for one week. The shampoo or lotion is rinsed off after 10 minutes.</p><p></p><p class="bulletIndent1">In the United States, unlike the higher concentrations of <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a>, selenium sulfide 1% shampoo can be obtained without a prescription. Although this formulation is sometimes used for tinea versicolor in clinical practice, its efficacy for tinea versicolor has not been studied.</p><p></p><p class="bulletIndent1">Some patients may find the odor of <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> unpleasant [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In a trial that compared <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> 2.5% shampoo applied once daily for seven days with oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> (at a dose of 200 mg once daily for five days) in 40 patients with tinea versicolor, complete clinical responses (resolution of scale, erythema, and pruritus) occurred in 85 percent of patients treated with itraconazole versus 80 percent of patients treated with selenium sulfide three weeks after the end of treatment [<a href="#rid41">41</a>]. However, among the complete clinical responders, microscopy remained positive in seven patients in the itraconazole group and in none in the selenium sulfide group.</p><p></p><p class="bulletIndent1">In another randomized trial (n = 167), application of <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> 2.5% lotion, selenium sulfide 2.5% lotion with added colorants, or vehicle for 10 minutes for seven days was associated with mycologic cure rates of 87, 71, and 16 percent, respectively [<a href="#rid42">42</a>]. The efficacy analysis excluded 35 patients who did not complete the study.</p><p></p><p class="bulletIndent1">Other randomized trials comparing <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> shampoo with bifonazole solution or <a class="drug drug_general" data-topicid="9400" href="/d/drug information/9400.html" rel="external">econazole</a> 1% shampoo suggest similar benefit of selenium sulfide therapy [<a href="#rid43">43,44</a>].</p><p></p><p class="headingAnchor" id="H2340889841"><span class="h3">Alternative therapy</span><span class="headingEndMark"> — </span>Benefits of <a class="drug drug_general" data-topicid="10237" href="/d/drug information/10237.html" rel="external">zinc pyrithione</a> 1% shampoo for tinea versicolor include the ease of shampoo application and the wide nonprescription availability of this product. However, compared with <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> and <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> (also available in shampoo), clinical trial data for zinc pyrithione are more limited and have focused on a longer course of treatment.</p><p class="headingAnchor" id="H21493682"><span class="h4">Zinc pyrithione</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10237" href="/d/drug information/10237.html" rel="external">Zinc pyrithione</a> 1% shampoo may be administered as one five-minute application per day for two weeks. Subsequently, the shampoo is rinsed off the skin. In the United States, this agent does not require a prescription.</p><p>In a controlled trial that included 40 patients with tinea versicolor, <a class="drug drug_general" data-topicid="10237" href="/d/drug information/10237.html" rel="external">zinc pyrithione</a> 1% shampoo applied for five minutes per day for two weeks was more effective than shampoo vehicle [<a href="#rid45">45</a>]. Four weeks after the end of treatment, none of the 20 patients treated with zinc pyrithione 1% shampoo had positive microscopy or evidence of Wood's light fluorescence compared with positive microscopy in 14 of 20 patients (70 percent) in the shampoo vehicle group and positive fluorescence in all patients in the shampoo vehicle group.</p><p class="headingAnchor" id="H13"><span class="h2">Refractory disease or extensive disease</span><span class="headingEndMark"> — </span>Oral antifungal therapy is typically reserved for tinea versicolor that is refractory to topical therapy, recurs frequently, or is associated with a scenario in which adequate application of topical therapy is not feasible (eg, extensive disease or limited ability of the patient to administer topical treatment)  (<a class="graphic graphic_algorithm graphicRef142461" href="/d/graphic/142461.html" rel="external">algorithm 1</a>) [<a href="#rid7">7,27</a>]. Oral antifungal therapy is not preferred for most patients because of greater risk for drug interactions and systemic adverse effects compared with topical therapy. When oral treatment is necessary, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> is typically used  (<a class="graphic graphic_table graphicRef100541" href="/d/graphic/100541.html" rel="external">table 1A</a>).</p><p class="headingAnchor" id="H2634346934"><span class="h3">Confirming treatment failure</span><span class="headingEndMark"> — </span>Prior to assuming a treatment for tinea versicolor is ineffective, the patient should be evaluated to confirm persistent infection, and potential reasons for treatment failure should be assessed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation of skin findings</strong> – Persistent hypopigmentation or hyperpigmentation is not a reliable indicator of treatment failure. Skin discoloration can persist for weeks to a few months after successful treatment. If feasible, active infection should be confirmed with a positive KOH preparation. The presence of the characteristic fine scale of tinea versicolor is a clinical sign that suggests active infection. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for reasons for inefficacy</strong> – The possibilities of an incorrect diagnosis and inadequate treatment administration should be considered when there is an apparent treatment failure.</p><p></p><p>Of note, resistance to topical therapy, frequent recurrence, or unusually severe tinea versicolor may occur in the setting of underlying immunodeficiency.</p><p class="headingAnchor" id="H2602674292"><span class="h3">Treatment selection</span><span class="headingEndMark"> — </span>When topical treatment is ineffective, options include switching to a different topical therapy or proceeding to oral antifungal therapy  (<a class="graphic graphic_algorithm graphicRef142461" href="/d/graphic/142461.html" rel="external">algorithm 1</a>).</p><p>Oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> and oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> are the preferred antifungal therapies for patients who require oral treatment. Selection between these therapies is based upon regimen preference, patient comorbidities, and consideration of drug interactions. We treat most patients with fluconazole because of a more favorable adverse effect profile and fewer serious drug interactions compared with itraconazole. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Oral fluconazole</span><span class="headingEndMark"> — </span>Various regimens for <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> have been utilized [<a href="#rid21">21,46</a>]. Our preferred fluconazole regimen for tinea versicolor in adults is a single 300 mg dose taken <strong>once weekly</strong> for two weeks [<a href="#rid46">46</a>].</p><p>One of the largest trials was an open, randomized trial (n = 608) that compared <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> doses of 150 mg once weekly for four weeks, 300 mg once weekly for four weeks, and 300 mg given once and then repeated in two weeks [<a href="#rid47">47</a>]. After the initial dose of fluconazole, subsequent doses were given only if patients exhibited clinical or microscopic evidence of infection. Mycologic cure rates at the last follow-up visit were 78, 93, and 87 percent, respectively, with both 300 mg regimens superior to the 150 mg dose regimen.</p><p><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> given as 300 mg per week for two weeks was assessed in other studies. In an open, randomized trial, fluconazole 300 mg per week for two weeks was superior to both a single 450 mg dose of fluconazole and a 200 mg dose of <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> given for seven days (97, 70, and 80 percent of patients, respectively, achieved mycologic cure one month after the end of treatment) [<a href="#rid48">48</a>]. In a small, uncontrolled study, fluconazole 300 mg once weekly for two weeks was associated with mycologic and clinical cure in 75 percent of patients at week 4 [<a href="#rid49">49</a>].</p><p>In an uncontrolled study of 24 individuals with extensive or recurrent tinea versicolor treated with a single 400 mg dose of <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, 74 percent had resolution of clinical disease three weeks after treatment [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H579255091"><span class="h3">Oral itraconazole</span><span class="headingEndMark"> — </span>Various regimens for oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> have been utilized [<a href="#rid21">21,46</a>]. Our preferred regimen for itraconazole for adults is 200 mg per day for five days. Some authors utilize a seven-day treatment course for extensive disease [<a href="#rid46">46</a>].</p><p>Small, primarily open, randomized trials have reported mycologic cure rates between 50 and 96 percent for 200 mg of <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> daily for five days and between 70 and 90 percent for 200 mg of itraconazole daily for seven days [<a href="#rid21">21,46</a>]. A difference in efficacy has not been proven. In an open, randomized trial that directly compared these regimens (n = 28), all patients exhibited clinical improvement by four weeks after treatment, and both clinical resolution and negative cultures were identified in 10 of 13 patients (77 percent) treated for five days and in 13 of 15 patients (87 percent) treated for seven days [<a href="#rid51">51</a>]. An analysis for statistical significance was not performed.</p><p>Data conflict on the efficacy of a single 400 mg dose of <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>. In an open, randomized trial (n = 50), a single 400 mg dose was as effective as 200 mg daily for seven days (mycologic cure at six weeks in 85 and 90 percent of patients, respectively) [<a href="#rid52">52</a>]. However, a low rate of response (based upon culture results) was reported in a trial (n = 40) that compared a single 400 mg dose of <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> and a single 400 mg dose of itraconazole (65 percent of patients given fluconazole versus 20 percent of patients given itraconazole were culture negative after eight weeks) [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2662269480"><span class="h3">Oral antifungal drugs to avoid</span><span class="headingEndMark"> — </span>In contrast to topical <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, oral terbinafine is <strong>not</strong> considered effective [<a href="#rid54">54</a>]. Oral terbinafine may not be secreted in sufficient levels in sweat to treat tinea versicolor adequately [<a href="#rid21">21</a>]. Oral <a class="drug drug_general" data-topicid="8502" href="/d/drug information/8502.html" rel="external">griseofulvin</a> has also <strong>not</strong> demonstrated efficacy for tinea versicolor.</p><p>Oral <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> should <strong>not</strong> be used for the treatment of tinea versicolor due to safety concerns [<a href="#rid55">55,56</a>]. Although oral ketoconazole was effective for tinea versicolor in small, randomized trials [<a href="#rid57">57,58</a>], life-threatening hepatotoxicity and adrenal insufficiency, along with multiple potential drug-drug interactions, have been reported with oral ketoconazole therapy. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Ketoconazole'</a>.)</p><p class="headingAnchor" id="H76227917"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Additional topical therapies have been used for the treatment of tinea versicolor.</p><p class="headingAnchor" id="H3204195096"><span class="h3">Topical ciclopirox</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9263" href="/d/drug information/9263.html" rel="external">ciclopirox</a> olamine 1% cream appeared effective for tinea versicolor and superior to <a class="drug drug_general" data-topicid="9287" href="/d/drug information/9287.html" rel="external">clotrimazole</a> 1% cream in two randomized trials performed by the same investigators [<a href="#rid59">59</a>]. In the trial that compared twice-daily application of ciclopirox olamine 1% cream for two weeks with vehicle (n = 153), both clinical and mycologic cure were present in 49 percent of 73 patients in the ciclopirox group and in 24 percent of 72 patients in the vehicle group at the end of two weeks of treatment. In the trial that compared twice-daily application of ciclopirox olamine 1% cream for two weeks with twice-daily application of clotrimazole 1% cream (n = 122), this endpoint occurred in 77 percent of 60 patients in the ciclopirox group compared with 45 percent of 53 patients in the clotrimazole group.</p><p class="headingAnchor" id="H1936090866"><span class="h3">Other</span><span class="headingEndMark"> — </span>Whitfield ointment (3% salicylic acid and 6% benzoic acid in an emulsifying base) [<a href="#rid60">60,61</a>] and <a class="drug drug_general" data-topicid="83320" href="/d/drug information/83320.html" rel="external">sulfur-salicylic acid</a> shampoo [<a href="#rid62">62</a>] appeared effective for tinea versicolor in small, randomized trials but may cause skin irritation in a minority of patients. Small, uncontrolled studies suggest that propylene glycol [<a href="#rid63">63</a>] and <a class="drug drug_general" data-topicid="8811" href="/d/drug information/8811.html" rel="external">benzoyl peroxide</a> [<a href="#rid64">64</a>] may also improve tinea versicolor.</p><p>Uncontrolled studies suggest benefit of topical <a class="drug drug_general" data-topicid="9675" href="/d/drug information/9675.html" rel="external">naftifine</a> for tinea versicolor [<a href="#rid20">20</a>]. An unpublished, randomized trial suggests benefit of topical <a class="drug drug_general" data-topicid="9177" href="/d/drug information/9177.html" rel="external">butenafine</a> [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H20"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Prophylactic therapy is an option for patients who experience frequent recurrences of tinea versicolor (eg, multiple recurrences per year), particularly during warm seasons. However, data on prophylactic therapy are limited. In our experience, prophylaxis with topical <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> 2.25% shampoo or <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% shampoo applied to the entire body for 10 minutes once per month has seemed beneficial.</p><p>Oral antifungal prophylactic therapy is an alternative approach for patients in whom topical therapy is not effective or feasible. Oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> (at a dose of 200 mg twice daily given for <strong>one day</strong> per month) is a reasonable regimen for adults. In a six-month, randomized trial (n = 209), a greater percentage of patients were free of recurrent disease after prophylactic treatment with itraconazole (at a dose of 200 mg twice daily for one day per month) than with placebo (88 versus 57 percent, respectively) [<a href="#rid66">66</a>]. (See <a class="local">'Other therapies'</a> above.)</p><p class="headingAnchor" id="H131844268"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/17233.html" rel="external">"Patient education: Tinea versicolor (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Tinea versicolor is a common superficial fungal skin infection that occurs most often in adolescents and young adults. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Tinea versicolor is not a dermatophyte infection. The causative organisms are saprophytic, lipid-dependent yeasts in the genus <em>Malassezia</em> (formerly known as <em>Pityrosporum</em>). <em>Malassezia</em> yeasts are a component of normal skin flora. The reasons for the development of tinea versicolor are likely to be multifactorial, involving both exogenous and endogenous factors. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Patients with tinea versicolor exhibit hypopigmented, hyperpigmented, or erythematous macules, patches, or thin plaques  (<a class="graphic graphic_picture graphicRef100026 graphicRef100022 graphicRef100020 graphicRef100019 graphicRef100021" href="/d/graphic/100026.html" rel="external">picture 1A-E</a>). Fine scale that becomes more apparent when lesions are scraped for microscopy is often present. The upper trunk and proximal upper extremities are the most common sites of involvement. Less often, facial or intertriginous areas are affected  (<a class="graphic graphic_picture graphicRef100025 graphicRef100024" href="/d/graphic/100025.html" rel="external">picture 3A-B</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A diagnosis of tinea versicolor may be strongly suspected based upon the physical examination. A potassium hydroxide (KOH) preparation demonstrating short hyphae and yeast cells confirms the diagnosis  (<a class="graphic graphic_picture graphicRef58965" href="/d/graphic/58965.html" rel="external">picture 4</a>). The appearance of the fungal elements in the KOH preparation is often described as "spaghetti and meatballs." (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General approach </strong>– For most patients with tinea versicolor, we suggest treatment with a topical azole antifungal drug, topical <a class="drug drug_general" data-topicid="9677" href="/d/drug information/9677.html" rel="external">terbinafine</a>, or topical <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> rather than other therapies  (<a class="graphic graphic_algorithm graphicRef142461" href="/d/graphic/142461.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef100541" href="/d/graphic/100541.html" rel="external">table 1A</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Factors such as treatment availability, patient preference, and cost influence selection among these treatments. <a class="drug drug_general" data-topicid="10237" href="/d/drug information/10237.html" rel="external">Zinc pyrithione</a> shampoo is a reasonable alternative; however, efficacy data are more limited. (See <a class="local">'General principles'</a> above and <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2">We frequently treat with <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% shampoo because of ease of application and evidence for efficacy of a short course of treatment. (See <a class="local">'Topical azole antifungal drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Topical therapy ineffective or not feasible</strong>:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Confirmation of active infection</strong> – Reassessment of the diagnosis and confirmation of active infection are important if tinea versicolor appears to fail to respond to treatment. Skin discoloration may persist for weeks to a few months after successful treatment. (See <a class="local">'Confirming treatment failure'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Treatment selection</strong> – For patients in whom topical therapy is not effective or feasible (eg, adequate application not feasible due to extent of disease or patient ability), we suggest oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> rather than other treatments  (<a class="graphic graphic_algorithm graphicRef142461" href="/d/graphic/142461.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef100541" href="/d/graphic/100541.html" rel="external">table 1A</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> is a reasonable alternative. Due to safety concerns, oral <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> should <strong>not</strong> be used for treatment. (See <a class="local">'Refractory disease or extensive disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frequent recurrences </strong>– Recurrent tinea versicolor is common. For patients who experience multiple recurrences per year and who desire prophylaxis, we suggest topical prophylactic therapy rather than oral prophylactic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically use once-monthly application of <a class="drug drug_general" data-topicid="9885" href="/d/drug information/9885.html" rel="external">selenium sulfide</a> 2.25% shampoo or <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> 2% shampoo.</p><p></p><p class="bulletIndent2">Patients for whom topical prophylactic therapy is ineffective can be treated with oral prophylactic therapy. We typically prescribe <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> taken for one day per month during the warm months of the year. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bouassida S, Boudaya S, Ghorbel R, et al. [Pityriasis versicolor in children: a retrospective study of 164 cases]. Ann Dermatol Venereol 1998; 125:581.</a></li><li><a class="nounderline abstract_t">Nanda A, Kaur S, Bhakoo ON, et al. Pityriasis (tinea) versicolor in infancy. Pediatr Dermatol 1988; 5:260.</a></li><li><a class="nounderline abstract_t">Jena DK, Sengupta S, Dwari BC, Ram MK. Pityriasis versicolor in the pediatric age group. Indian J Dermatol Venereol Leprol 2005; 71:259.</a></li><li><a class="nounderline abstract_t">Wyre HW Jr, Johnson WT. Neonatal pityriasis versicolor. Arch Dermatol 1981; 117:752.</a></li><li><a class="nounderline abstract_t">Faergemann J, Fredriksson T. Experimental infections in rabbits and humans with Pityrosporum orbiculare and P. ovale. J Invest Dermatol 1981; 77:314.</a></li><li><a class="nounderline abstract_t">BURKE RC. Tinea versicolor: susceptibility factors and experimental infection in human beings. J Invest Dermatol 1961; 36:389.</a></li><li><a class="nounderline abstract_t">Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin 2003; 21:413.</a></li><li><a class="nounderline abstract_t">Morishita N, Sei Y. Microreview of Pityriasis versicolor and Malassezia species. Mycopathologia 2006; 162:373.</a></li><li><a class="nounderline abstract_t">Prohic A, Ozegovic L. Malassezia species isolated from lesional and non-lesional skin in patients with pityriasis versicolor. Mycoses 2007; 50:58.</a></li><li><a class="nounderline abstract_t">Karakaş M, Turaç-Biçer A, Ilkit M, et al. Epidemiology of pityriasis versicolor in Adana, Turkey. J Dermatol 2009; 36:377.</a></li><li><a class="nounderline abstract_t">Schwartz RA. Superficial fungal infections. Lancet 2004; 364:1173.</a></li><li><a class="nounderline abstract_t">Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002; 16:19.</a></li><li><a class="nounderline abstract_t">Galadari I, el Komy M, Mousa A, et al. Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol 1992; 31:253.</a></li><li><a class="nounderline abstract_t">Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 1978; 71:205.</a></li><li><a class="nounderline abstract_t">Faergemann J. Pityriasis versicolor. Semin Dermatol 1993; 12:276.</a></li><li><a class="nounderline abstract_t">Hafez M, el-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica 1985; 171:86.</a></li><li><a class="nounderline abstract_t">He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses 2008; 51:55.</a></li><li><a class="nounderline abstract_t">Güleç AT, Demirbilek M, Seçkin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol 2003; 49:187.</a></li><li><a class="nounderline abstract_t">Alam HS, Ward JM, Davis LS. Generalized tinea versicolor following initiation of ixekizumab therapy. JAAD Case Rep 2021; 18:54.</a></li><li><a class="nounderline abstract_t">Leung AK, Barankin B, Lam JM, et al. Tinea versicolor: an updated review. Drugs Context 2022; 11.</a></li><li><a class="nounderline abstract_t">Gupta AK, Foley KA. Antifungal Treatment for Pityriasis Versicolor. J Fungi (Basel) 2015; 1:13.</a></li><li><a class="nounderline abstract_t">Saunte DML, Gaitanis G, Hay RJ. Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment. Front Cell Infect Microbiol 2020; 10:112.</a></li><li><a class="nounderline abstract_t">Kaur I, Jakhar D, Singal A. Dermoscopy in the Evaluation of Pityriasis Versicolor: A Cross Sectional Study. Indian Dermatol Online J 2019; 10:682.</a></li><li><a class="nounderline abstract_t">Zhou H, Tang XH, De Han J, Chen MK. Dermoscopy as an ancillary tool for the diagnosis of pityriasis versicolor. J Am Acad Dermatol 2015; 73:e205.</a></li><li><a class="nounderline abstract_t">Mathur M, Acharya P, Karki A, et al. Dermoscopic pattern of pityriasis versicolor. Clin Cosmet Investig Dermatol 2019; 12:303.</a></li><li><a class="nounderline abstract_t">Stiube A, Jenni D, Wiederkehr L, et al. Terra Firme-Forme Dermatosis Diagnostic Sign and Treatment: A Case Report. Case Rep Dermatol 2019; 11:108.</a></li><li><a class="nounderline abstract_t">Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34:287.</a></li><li><a class="nounderline abstract_t">Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010; 146:1132.</a></li><li><a class="nounderline abstract_t">Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother 2005; 6:165.</a></li><li><a class="nounderline abstract_t">Rekacewicz I, Guillaume JC, Benkhraba F, et al. [A double-blind placebo-controlled study of a 2 percent foaming lotion of ketoconazole in a single application in the treatment of pityriasis versicolor]. Ann Dermatol Venereol 1990; 117:709.</a></li><li><a class="nounderline abstract_t">Hernández-Pérez E. A comparison between one and two weeks' treatment with bifonazole in pityriasis versicolor. J Am Acad Dermatol 1986; 14:561.</a></li><li><a class="nounderline abstract_t">Galimberti RL, Bonino M, Flores V, et al. Ultra-short topical treatment of pityriasis versicolor with 2.5% bifonazole cream. Clin Exp Dermatol 1993; 18:25.</a></li><li><a class="nounderline abstract_t">Lange DS, Richards HM, Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 1998; 39:944.</a></li><li><a class="nounderline abstract_t">Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15:500.</a></li><li><a class="nounderline abstract_t">Balwada RP, Jain VK, Dayal S. A double-blind comparison of 2% ketoconazole and 1% clotrimazole in the treatment of pityriasis versicolor. Indian J Dermatol Venereol Leprol 1996; 62:298.</a></li><li><a class="nounderline abstract_t">Budimulja U, Paul C. One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. J Dermatolog Treat 2002; 13:39.</a></li><li><a class="nounderline abstract_t">Aste N, Pau M, Pinna AL, et al. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses 1991; 34:353.</a></li><li><a class="nounderline abstract_t">Chopra V, Jain VK. Comparative study of topical terbinafine and topical ketoconazole in pityriasis versicolor. Indian J Dermatol Venereol Leprol 2000; 66:299.</a></li><li><a class="nounderline abstract_t">Sharma J, Kaushal J, Aggarwal K. A Comparative Study of Efficacy and Safety of Eberconazole versus Terbinafine in Patients of Tinea Versicolor. Indian J Dermatol 2018; 63:53.</a></li><li><a class="nounderline abstract_t">Rad F, Nik-Khoo B, Yaghmaee R, Gharibi F. Terbinafin 1% Cream and Ketoconazole 2% Cream in the Treatment of Pityriasis Versicolor: A randomized comparative clinical trial. Pak J Med Sci 2014; 30:1273.</a></li><li><a class="nounderline abstract_t">del Palacio Hernanz A, Delgado Vicente S, Menéndez Ramos F, Rodríguez-Noriega Belaustegui A. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987; 9 Suppl 1:S121.</a></li><li><a class="nounderline abstract_t">Sánchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11:235.</a></li><li><a class="nounderline abstract_t">Chu AC. Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica 1984; 169 Suppl 1:81.</a></li><li><a class="nounderline abstract_t">Katsambas A, Rigopoulos D, Antoniou C, et al. Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: a single-blind randomized clinical study. Int J Dermatol 1996; 35:667.</a></li><li><a class="nounderline abstract_t">Fredriksson T, Faergemann J. Double-blind comparison of a zinc pyrithione shampoo and its shampoo base in the treatment of tinea versicolor. Cutis 1983; 31:436.</a></li><li><a class="nounderline abstract_t">Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg 2014; 18:79.</a></li><li><a class="nounderline abstract_t">Amer MA. Fluconazole in the treatment of tinea versicolor. Egyptian Fluconazole Study Group. Int J Dermatol 1997; 36:940.</a></li><li><a class="nounderline abstract_t">Montero-Gei F, Robles ME, Suchil P. Fluconazole vs. itraconazole in the treatment of tinea versicolor. Int J Dermatol 1999; 38:601.</a></li><li><a class="nounderline abstract_t">Karakaş M, Durdu M, Memişoğlu HR. Oral fluconazole in the treatment of tinea versicolor. J Dermatol 2005; 32:19.</a></li><li><a class="nounderline abstract_t">Faergemann J. Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol 1992; 72:74.</a></li><li><a class="nounderline abstract_t">Galimberti RL, Villalba I, Galarza S, et al. Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia furfur produced during treatment. Rev Infect Dis 1987; 9 Suppl 1:S134.</a></li><li><a class="nounderline abstract_t">Köse O, Bülent Taştan H, Riza Gür A, Kurumlu Z. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002; 13:77.</a></li><li><a class="nounderline abstract_t">Partap R, Kaur I, Chakrabarti A, Kumar B. Single-dose fluconazole versus itraconazole in pityriasis versicolor. Dermatology 2004; 208:55.</a></li><li><a class="nounderline abstract_t">Leeming JP, Sansom JE, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol 1997; 137:764.</a></li><li class="breakAll">European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&amp;mid=WC0b01ac058004d5c1 (Accessed on July 26, 2013).</li><li class="breakAll">www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm502073.htm (Accessed on May 23, 2016).</li><li><a class="nounderline abstract_t">Hay RJ, Midgeley G. Short course ketoconazole therapy in pityriasis versicolor. Clin Exp Dermatol 1984; 9:571.</a></li><li><a class="nounderline abstract_t">Zaias N. Pityriasis versicolor with ketoconazole. J Am Acad Dermatol 1989; 20:703.</a></li><li><a class="nounderline abstract_t">Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7:574.</a></li><li><a class="nounderline abstract_t">Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol 1973; 89:297.</a></li><li><a class="nounderline abstract_t">Clayton R, Du Vivier A, Savage M. Double-blind trial of 1% clotrimazole cream and Whitfield ointment in the treatment of pityriasis versicolor. Arch Dermatol 1977; 113:849.</a></li><li><a class="nounderline abstract_t">Bamford JT. Treatment of tinea versicolor with sulfur-salicylic shampoo. J Am Acad Dermatol 1983; 8:211.</a></li><li><a class="nounderline abstract_t">Faergemann J, Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol 1980; 60:92.</a></li><li><a class="nounderline abstract_t">Prestia AE. Topical benzoyl peroxide for the treatment of tinea versicolor. J Am Acad Dermatol 1983; 9:277.</a></li><li><a class="nounderline abstract_t">Gupta AK. Butenafine: an update of its use in superficial mycoses. Skin Therapy Lett 2002; 7:1.</a></li><li><a class="nounderline abstract_t">Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol 2002; 138:69.</a></li></ol></div><div id="topicVersionRevision">Topic 4039 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9805544" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : [Pityriasis versicolor in children: a retrospective study of 164 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3068655" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pityriasis (tinea) versicolor in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394435" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pityriasis versicolor in the pediatric age group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7316542" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neonatal pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7264365" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Experimental infections in rabbits and humans with Pityrosporum orbiculare and P. ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13689079" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tinea versicolor: susceptibility factors and experimental infection in human beings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12956196" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17146580" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Microreview of Pityriasis versicolor and Malassezia species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17302750" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Malassezia species isolated from lesional and non-lesional skin in patients with pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583685" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of pityriasis versicolor in Adana, Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451228" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Superficial fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11952286" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1378819" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/99481" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Identification of tyrosinase inhibitors in cultures of Pityrosporum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8312142" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4043474" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Genetic susceptibility in pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076596" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The genetic epidemiology of tinea versicolor in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12894063" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Superficial fungal infections in 102 renal transplant recipients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34815994" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Generalized tinea versicolor following initiation of ixekizumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36452877" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tinea versicolor: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29376896" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antifungal Treatment for Pityriasis Versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32266163" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31807448" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dermoscopy in the Evaluation of Pityriasis Versicolor: A Cross Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26568350" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dermoscopy as an ancillary tool for the diagnosis of pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31118732" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dermoscopic pattern of pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31123454" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Terra Firme-Forme Dermatosis Diagnostic Sign and Treatment: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8642095" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956647" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pityriasis versicolor: a systematic review of interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15757415" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pityriasis versicolor: a review of pharmacological treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2073061" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [A double-blind placebo-controlled study of a 2 percent foaming lotion of ketoconazole in a single application in the treatment of pityriasis versicolor].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3514702" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A comparison between one and two weeks' treatment with bifonazole in pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8440048" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ultra-short topical treatment of pityriasis versicolor with 2.5% bifonazole cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843006" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3760275" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948094" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A double-blind comparison of 2% ketoconazole and 1% clotrimazole in the treatment of pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006138" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1803242" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20877107" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparative study of topical terbinafine and topical ketoconazole in pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29527026" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Comparative Study of Efficacy and Safety of Eberconazole versus Terbinafine in Patients of Tinea Versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25674122" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Terbinafin 1% Cream and Ketoconazole 2% Cream in the Treatment of Pityriasis Versicolor: A randomized comparative clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3027836" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6384285" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Double-blind efficacy study of selenium sulfide in tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6396117" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8876302" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: a single-blind randomized clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6342980" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Double-blind comparison of a zinc pyrithione shampoo and its shampoo base in the treatment of tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636433" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466206" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fluconazole in the treatment of tinea versicolor. Egyptian Fluconazole Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487450" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fluconazole vs. itraconazole in the treatment of tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841655" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Oral fluconazole in the treatment of tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1350156" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of pityriasis versicolor with a single dose of fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3027839" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia furfur produced during treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12060506" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14730238" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Single-dose fluconazole versus itraconazole in pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415238" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Susceptibility of Malassezia furfur subgroups to terbinafine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415238" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Susceptibility of Malassezia furfur subgroups to terbinafine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415238" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Susceptibility of Malassezia furfur subgroups to terbinafine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6094055" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Short course ketoconazole therapy in pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2654210" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pityriasis versicolor with ketoconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2865009" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4582719" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/326197" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Double-blind trial of 1% clotrimazole cream and Whitfield ointment in the treatment of pityriasis versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6338064" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of tinea versicolor with sulfur-salicylic shampoo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6153851" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Propylene glycol in the treatment of tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6886121" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Topical benzoyl peroxide for the treatment of tinea versicolor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12432425" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Butenafine: an update of its use in superficial mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790169" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
